Financing ·
NeOnc raises $15M in registered direct offering and redeems Series A Preferred for $5.8M
NTHINeonc Technologies Holdings, Inc.
NeOnc Technologies Holdings raised approximately $15 million through a registered direct offering priced at-the-market with healthcare-focused institutional investors on September 10, 2026. The company used a portion of the proceeds to redeem all 6,000 outstanding shares of its Series A Convertible Preferred Stock for approximately $5.8 million in cash, eliminating potential dilution. For the third quarter ended September 30, 2026, NeOnc reported a net loss of $4.4 million, down from $8.6 million in the prior year period, with total operating expenses declining to $5.8 million. The company also announced board appointments and highlighted clinical progress for its NEO100 and NEO212 programs ahead of an upcoming data presentation at the Society for Neuro-Oncology Annual Meeting. NeOnc Technologies Holdings is a clinical-stage biopharmaceutical company developing therapies for central nervous system cancers.